Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ashaye A
- Shi L
- Aldoss I
- Vachhani P
- Rocha V
- Papayannidis C
- Leonard JT
- Baer MR
- Ribera JM
- McCloskey J
- Wang J
- Gao S
- Rane D
- Guo S
Grupos
Abstract
In the Phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy and comparable safety profile versus imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Here we report patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L. Primary PRO domains included FACT-G physical well-being, FACT-Leu subscale (FACT-LeuS), Trial Outcome Index (TOI), FACT-Leu total score, FACT-G total score, and EQ-5D visual analogue scale. Differences in least-squares mean score changes from baseline to the end of induction (EOI)/consolidation (EOC) and time to confirmed improvement/deterioration were analyzed. Overall treatment tolerability was assessed using the FACT-GP5. Analyses included 238 patients (ponatinib 159, imatinib 79) with =1 PRO assessment. Least-squares mean changes from baseline favored ponatinib, with significant and meaningful differences in FACT-LeuS, TOI, and FACT-Leu total score at EOI and across the primary domains except for FACT-LeuS at EOC. Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures. Ponatinib-treated patients tended to report being less bothered by treatment side effects as assessed by FACT-GP5. These findings highlight ponatinib's potentially favorable impact on health-related quality of life, supporting its use as frontline treatment for Ph+ ALL.
© 2025. The Author(s).
Datos de la publicación
- ISSN/ISSNe:
- 0887-6924, 1476-5551
- Tipo:
- Article
- Páginas:
- 1342-1350
- PubMed:
- 40240572
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 4,030 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
LEUKEMIA SPRINGERNATURE
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- QUALITY-OF-LIFE; CHRONIC MYELOID-LEUKEMIA; KINASE DOMAIN MUTATIONS; FUNCTIONAL ASSESSMENT; BOSUTINIB SKI-606; CANCER-THERAPY; STANDARD; INHIBITOR; VERSION; SCORES
Portal de investigación